Second Sight Medical Products Stock Price, News & Analysis (NASDAQ:EYES)

$1.14 -0.05 (-4.20 %)
(As of 11/21/2017 04:00 PM ET)
Previous Close$1.19
Today's Range$1.14 - $1.20
52-Week Range$0.90 - $2.83
Volume375,576 shs
Average Volume492,102 shs
Market Capitalization$66.46 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Second Sight Medical Products (NASDAQ:EYES)

Second Sight Medical Products logoSecond Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company's product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company's Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient's glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.


Industry, Sector and Symbol:
  • Industry: Medical Devices & Implants
  • Sub-Industry: N/A
  • Sector: Healthcare
  • Symbol: NASDAQ:EYES
  • CUSIP: N/A
  • Web: www.secondsight.com
Debt:
  • Current Ratio: 2.90%
  • Quick Ratio: 2.37%
Sales & Book Value:
  • Annual Sales: $3.98 million
  • Price / Sales: 16.27
  • Book Value: $0.26 per share
  • Price / Book: 4.38
Profitability:
  • Trailing EPS: ($0.67)
  • Net Income: $-33,170,000.00
  • Net Margins: -565.12%
  • Return on Equity: -171.77%
  • Return on Assets: -131.02%
Misc:
  • Employees: 110
  • Outstanding Shares: 56,810,000
 

Frequently Asked Questions for Second Sight Medical Products (NASDAQ:EYES)

What is Second Sight Medical Products' stock symbol?

Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES."

How were Second Sight Medical Products' earnings last quarter?

Second Sight Medical Products, Inc. (NASDAQ:EYES) announced its quarterly earnings results on Thursday, November, 2nd. The medical device company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.14) by $0.02. The medical device company earned $1.61 million during the quarter, compared to the consensus estimate of $1.54 million. Second Sight Medical Products had a negative net margin of 565.12% and a negative return on equity of 171.77%. View Second Sight Medical Products' Earnings History.

Where is Second Sight Medical Products' stock going? Where will Second Sight Medical Products' stock price be in 2017?

1 analysts have issued twelve-month price objectives for Second Sight Medical Products' shares. Their predictions range from $5.00 to $5.00. On average, they expect Second Sight Medical Products' share price to reach $5.00 in the next year. View Analyst Ratings for Second Sight Medical Products.

What are Wall Street analysts saying about Second Sight Medical Products stock?

Here are some recent quotes from research analysts about Second Sight Medical Products stock:

  • 1. According to Zacks Investment Research, "Second Sight Medical Products, Inc. is a medical device company. It develops, manufactures, and markets implantable prosthetic devices to restore some functional vision to blind patients. The Company provides Argus II system, an implantable neurostimulation device for the treatment of outer retinal degenerations, such as retinitis pigmentosa. Second Sight Medical Products, Inc. is headquartered in Sylmar, California. " (11/9/2017)
  • 2. HC Wainwright analysts commented, "We expect that the second pilot study could start in late 3Q17 or early 4Q17 and report top-line data by the end of 2017. Investors may recall that this second pilot study is double-masked and slated to enroll up to 45 subjects. The primary endpoint is the percentage of subjects achieving complete wound healing (based on staining) on day 3. Assuming that the second pilot study shows OBG’s ability to heal corneal defects faster than the standard of care, as was seen in the first pilot study, we believe that EyeGate may only need to conduct a single pivotal study in 2018 before filing for regulatory approval. We note that the FDA has permitted EyeGate to pursue U.S. regulatory clearance for OBG through the de novo 510(k) pathway." (8/8/2017)

Who are some of Second Sight Medical Products' key competitors?

Who are Second Sight Medical Products' key executives?

Second Sight Medical Products' management team includes the folowing people:

  • Robert J. Greenberg M.D. Ph.D., Chairman of the Board (Age 49)
  • Jonathan McGuire, President, Chief Executive Officer, Director (Age 54)
  • Frank Vandeputte, Vice President, General Manager
  • Gregoire Cosendai, Vice President - Clinical Affairs (Age 45)
  • Stephen D. Okland Jr., Commercial Vice President, U.S. and Canada (Age 53)
  • Edward David Randolph, Vice President - Manufacturing (Age 59)
  • David Murray Jacques, Vice President - Research & Development (Age 54)
  • William J. Link Ph.D., Independent Director (Age 71)
  • Aaron Mendelsohn, Independent Director (Age 66)
  • Matthew Jonathan Pfeffer, Independent Director (Age 60)

When did Second Sight Medical Products IPO?

(EYES) raised $32 million in an IPO on Wednesday, November 19th 2014. The company issued 3,500,000 shares at a price of $9.00 per share. MDB Capital Group, LLC served as the underwriter for the IPO.

How do I buy Second Sight Medical Products stock?

Shares of Second Sight Medical Products can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Second Sight Medical Products' stock price today?

One share of Second Sight Medical Products stock can currently be purchased for approximately $1.14.

How big of a company is Second Sight Medical Products?

Second Sight Medical Products has a market capitalization of $66.46 million and generates $3.98 million in revenue each year. The medical device company earns $-33,170,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis. Second Sight Medical Products employs 110 workers across the globe.

How can I contact Second Sight Medical Products?

Second Sight Medical Products' mailing address is 12744 San Fernando Rd Bldg 3, SYLMAR, CA 91342-3853, United States. The medical device company can be reached via phone at +1-818-8335000 or via email at [email protected]


MarketBeat Community Rating for Second Sight Medical Products (NASDAQ EYES)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  87 (Vote Outperform)
Underperform Votes:  87 (Vote Underperform)
Total Votes:  174
MarketBeat's community ratings are surveys of what our community members think about Second Sight Medical Products and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Second Sight Medical Products (NASDAQ:EYES)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.00 (338.60% upside)

Consensus Price Target History for Second Sight Medical Products (NASDAQ:EYES)

Price Target History for Second Sight Medical Products (NASDAQ:EYES)

Analysts' Ratings History for Second Sight Medical Products (NASDAQ:EYES)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/6/2017HC WainwrightReiterated RatingBuy$5.00N/AView Rating Details
7/26/2016Rodman & RenshawReiterated RatingBuy$16.00N/AView Rating Details
(Data available from 11/21/2015 forward)

Earnings

Earnings History and Estimates Chart for Second Sight Medical Products (NASDAQ:EYES)

Earnings by Quarter for Second Sight Medical Products (NASDAQ:EYES)

Earnings History by Quarter for Second Sight Medical Products (NASDAQ EYES)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017Q3 2017($0.14)($0.12)$1.54 million$1.61 millionViewN/AView Earnings Details
8/1/2017Q2 2017($0.14)($0.13)$1.43 million$2.24 millionViewListenView Earnings Details
5/3/2017Q1 2017($0.14)($0.18)$1.32 million$1.01 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.17)($0.24)$1.76 million$0.72 millionViewListenView Earnings Details
11/2/2016Q316($0.16)($0.15)$2.36 million$1.20 millionViewN/AView Earnings Details
7/28/2016Q216($0.15)($0.17)$2.66 million$1.04 millionViewListenView Earnings Details
4/28/2016Q116($0.16)($0.13)$1.38 million$1.05 millionViewListenView Earnings Details
3/3/2016Q415($0.14)($0.15)$2.47 million$2.40 millionViewN/AView Earnings Details
10/29/2015Q315($0.14)($0.13)$2.05 million$2.23 millionViewListenView Earnings Details
8/4/2015Q215($0.14)($0.14)$1.73 million$2.70 millionViewN/AView Earnings Details
5/13/2015Q115($0.12)$1.70 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Second Sight Medical Products (NASDAQ:EYES)
Current Year EPS Consensus Estimate: $-0.55 EPS
Next Year EPS Consensus Estimate: $-0.58 EPS

Dividends

Dividend History for Second Sight Medical Products (NASDAQ:EYES)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Second Sight Medical Products (NASDAQ EYES)

Insider Ownership Percentage: 50.90%
Institutional Ownership Percentage: 12.82%
Insider Trades by Quarter for Second Sight Medical Products (NASDAQ:EYES)
Institutional Ownership by Quarter for Second Sight Medical Products (NASDAQ:EYES)

Insider Trades by Quarter for Second Sight Medical Products (NASDAQ EYES)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/7/2017Gregg WilliamsDirectorBuy4,000,000$1.00$4,000,000.00View SEC Filing  
12/1/2016Robert J GreenbergChairmanSell1,950$1.96$3,822.00View SEC Filing  
6/3/2016Edward David RandolphVPSell5,104$4.01$20,467.04View SEC Filing  
6/2/2016Robert J GreenbergChairmanSell8,571$4.10$35,141.10View SEC Filing  
4/18/2016Robert J GreenbergChairmanSell8,223$5.27$43,335.21View SEC Filing  
12/7/2015Robert J. GreenbergChairmanSell17,969$5.30$95,235.70View SEC Filing  
12/4/2015Anne-Marie Juliette RipleyVPSell2,500$5.50$13,750.00View SEC Filing  
6/4/2015Anne-Marie Juliette RipleyVPSell4,371$15.00$65,565.00View SEC Filing  
6/3/2015Robert J GreenbergCEOSell150,000$14.04$2,106,000.00View SEC Filing  
5/27/2015Anne-Marie Juliette RipleyVPSell45,629$13.04$595,002.16View SEC Filing  
3/23/2015Robert J GreenbergCEOSell100,000$13.28$1,328,000.00View SEC Filing  
11/19/2014Gregg WilliamsDirectorBuy111,111$9.00$999,999.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Second Sight Medical Products (NASDAQ EYES)

Source:
DateHeadline
ETFs with exposure to Second Sight Medical Products, Inc. : November 20, 2017ETFs with exposure to Second Sight Medical Products, Inc. : November 20, 2017
finance.yahoo.com - November 20 at 7:17 PM
Second Sight Medical (EYES) Says OHTAC Recommends Public Funding for its Argus II Retinal Prosthesis System - StreetInsider.comSecond Sight Medical (EYES) Says OHTAC Recommends Public Funding for its Argus II Retinal Prosthesis System - StreetInsider.com
www.streetinsider.com - November 11 at 8:38 AM
Second Sight Medical (EYES) Announces FDA Expedited Access Pathway Designation for Orion Cortical Visual Prosthesis SystemSecond Sight Medical (EYES) Announces FDA Expedited Access Pathway Designation for Orion Cortical Visual Prosthesis System
www.streetinsider.com - November 10 at 2:40 PM
Second Sight Medical Products, Inc. :EYES-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017Second Sight Medical Products, Inc. :EYES-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
finance.yahoo.com - November 10 at 2:40 PM
Ontario Health Technology Advisory Committee Recommends Public Funding for Second Sight’s Argus II Retinal Prosthesis SystemOntario Health Technology Advisory Committee Recommends Public Funding for Second Sight’s Argus II Retinal Prosthesis System
finance.yahoo.com - November 10 at 2:40 PM
ETFs with exposure to Second Sight Medical Products, Inc. : November 10, 2017ETFs with exposure to Second Sight Medical Products, Inc. : November 10, 2017
finance.yahoo.com - November 10 at 2:40 PM
Second Sight Medical (EYES) Announces FDA Expedited Access Pathway Designation for Orion Cortical Visual ... - StreetInsider.comSecond Sight Medical (EYES) Announces FDA Expedited Access Pathway Designation for Orion Cortical Visual ... - StreetInsider.com
www.streetinsider.com - November 9 at 2:44 AM
Second Sight Receives FDA Expedited Access Pathway Designation for the Orion Cortical Visual Prosthesis SystemSecond Sight Receives FDA Expedited Access Pathway Designation for the Orion Cortical Visual Prosthesis System
finance.yahoo.com - November 9 at 2:44 AM
Second Sight Medical Products (EYES) CEO Will McGuire on Q3 ... - Seeking AlphaSecond Sight Medical Products' (EYES) CEO Will McGuire on Q3 ... - Seeking Alpha
seekingalpha.com - November 7 at 1:06 AM
Second Sight Medical Products (EYES) "Buy" Rating Reaffirmed at HC WainwrightSecond Sight Medical Products' (EYES) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - November 6 at 10:54 PM
Second Sight Medical Products, Inc. (EYES) Issues Quarterly  Earnings ResultsSecond Sight Medical Products, Inc. (EYES) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 3 at 3:50 PM
Second Sight Medical (EYES) Announces Argus II Final Medicare Hospital Outpatient Payment Rate for 2018 - StreetInsider.comSecond Sight Medical (EYES) Announces Argus II Final Medicare Hospital Outpatient Payment Rate for 2018 - StreetInsider.com
www.streetinsider.com - November 3 at 12:39 PM
Second Sight Announces Final Medicare Hospital Outpatient Payment Rate for 2018 for the Argus II Retinal Prosthesis SystemSecond Sight Announces Final Medicare Hospital Outpatient Payment Rate for 2018 for the Argus II Retinal Prosthesis System
finance.yahoo.com - November 2 at 7:44 PM
Second Sight Receives Full FDA Approval to Begin First Orion Human Clinical StudySecond Sight Receives Full FDA Approval to Begin First Orion Human Clinical Study
finance.yahoo.com - November 2 at 7:44 PM
Second Sight Reports Third Quarter 2017 Financial ResultsSecond Sight Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 2 at 7:44 PM
Second Sight Medical Products posts 3Q lossSecond Sight Medical Products posts 3Q loss
finance.yahoo.com - November 2 at 7:44 PM
Second Sight to Discuss Third Quarter 2017 Financial Results on November 2, 2017 Conference CallSecond Sight to Discuss Third Quarter 2017 Financial Results on November 2, 2017 Conference Call
finance.yahoo.com - October 26 at 12:14 PM
ETFs with exposure to Second Sight Medical Products, Inc. : October 24, 2017ETFs with exposure to Second Sight Medical Products, Inc. : October 24, 2017
finance.yahoo.com - October 24 at 11:29 PM
Second Sight Medical Products, Inc. (EYES) to Release Earnings on TuesdaySecond Sight Medical Products, Inc. (EYES) to Release Earnings on Tuesday
www.americanbankingnews.com - October 24 at 6:12 AM
Comparing Cerus (CERS) and Second Sight Medical Products (EYES)Comparing Cerus (CERS) and Second Sight Medical Products (EYES)
www.americanbankingnews.com - October 23 at 2:12 PM
Analyzing Second Sight Medical Products (EYES) & HeartWare International (HTWR)Analyzing Second Sight Medical Products (EYES) & HeartWare International (HTWR)
www.americanbankingnews.com - October 23 at 12:08 AM
Second Sight Announces Appointments of Frank Vandeputte as Vice President and General Manager, EMEA and Asia ... - Business Wire (press release)Second Sight Announces Appointments of Frank Vandeputte as Vice President and General Manager, EMEA and Asia ... - Business Wire (press release)
www.businesswire.com - October 19 at 7:16 PM
Pre-Open Movers 10/17: (SNCR) (EYES) (IMDZ) Higher; (BMI) (IPXL) (HOG) Lower (more...) - StreetInsider.comPre-Open Movers 10/17: (SNCR) (EYES) (IMDZ) Higher; (BMI) (IPXL) (HOG) Lower (more...) - StreetInsider.com
www.streetinsider.com - October 18 at 12:19 AM
Pre-Open Movers 10/17: (SNCR) (EYES) (IMDZ) Higher; (BMI) (IPXL) (HOG) Lower (more...)Pre-Open Movers 10/17: (SNCR) (EYES) (IMDZ) Higher; (BMI) (IPXL) (HOG) Lower (more...)
www.streetinsider.com - October 17 at 7:19 PM
Second Sight Receives Approval from Bundesinstitut für Arzneimittel und Medizinprodukte in Germany to Begin Study to Implant and Evaluate Argus II in Better-Sighted Retinitis ...Second Sight Receives Approval from Bundesinstitut für Arzneimittel und Medizinprodukte in Germany to Begin Study to Implant and Evaluate Argus II in Better-Sighted Retinitis ...
www.businesswire.com - October 17 at 7:19 PM
Second Sight Receives Approval from Bundesinstitut für Arzneimittel und Medizinprodukte in Germany to Begin Study to Implant and Evaluate Argus II in Better-Sighted Retinitis Pigmentosa PatientsSecond Sight Receives Approval from Bundesinstitut für Arzneimittel und Medizinprodukte in Germany to Begin Study to Implant and Evaluate Argus II in Better-Sighted Retinitis Pigmentosa Patients
finance.yahoo.com - October 17 at 7:18 PM
Second Sight Medical Products Inc (EYES) to Initiate Study of Argus II in Better-Sighted Retinitis Pigmentosa Patients; Shares Rose 5%Second Sight Medical Products Inc (EYES) to Initiate Study of Argus II in Better-Sighted Retinitis Pigmentosa Patients; Shares Rose 5%
finance.yahoo.com - October 17 at 7:18 PM
ETFs with exposure to Second Sight Medical Products, Inc. : October 13, 2017ETFs with exposure to Second Sight Medical Products, Inc. : October 13, 2017
finance.yahoo.com - October 13 at 4:06 PM
Second Sight Medical Products, Inc. (EYES) Upgraded to "Hold" by Zacks Investment ResearchSecond Sight Medical Products, Inc. (EYES) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - October 10 at 7:40 PM
Second Sight Medical Products (EYES) vs. St Jude Medical (STJ) Head to Head ContrastSecond Sight Medical Products (EYES) vs. St Jude Medical (STJ) Head to Head Contrast
www.americanbankingnews.com - October 6 at 10:34 PM
Second Sight Medical Products, Inc. :EYES-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017Second Sight Medical Products, Inc. :EYES-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017
finance.yahoo.com - October 2 at 2:45 PM
ETFs with exposure to Second Sight Medical Products, Inc. : October 2, 2017ETFs with exposure to Second Sight Medical Products, Inc. : October 2, 2017
finance.yahoo.com - October 2 at 2:45 PM
A historian says all of sci-fi shares the same major flaw — except one legendary novelA historian says all of sci-fi shares the same major flaw — except one legendary novel
www.businessinsider.com - September 29 at 2:22 PM
Head-To-Head Analysis: Second Sight Medical Products (EYES) versus Stryker Corporation (SYK)Head-To-Head Analysis: Second Sight Medical Products (EYES) versus Stryker Corporation (SYK)
www.americanbankingnews.com - September 16 at 12:10 AM
Cyberonics (CYBX) vs. Second Sight Medical Products (EYES) Head-To-Head AnalysisCyberonics (CYBX) vs. Second Sight Medical Products (EYES) Head-To-Head Analysis
www.americanbankingnews.com - September 13 at 4:30 PM
St Jude Medical (STJ) and Second Sight Medical Products (EYES) Critical ContrastSt Jude Medical (STJ) and Second Sight Medical Products (EYES) Critical Contrast
www.americanbankingnews.com - September 8 at 8:28 PM
Annual Rodman & Renshaw Global Investment Conference in New York on September 12 - Business Wire (press release)Annual Rodman & Renshaw Global Investment Conference in New York on September 12 - Business Wire (press release)
www.businesswire.com - September 5 at 8:14 PM
Second Sight to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York on September 12thSecond Sight to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York on September 12th
finance.yahoo.com - September 5 at 8:13 PM
Critical Contrast: Second Sight Medical Products (EYES) & RTI Surgical (RTIX)Critical Contrast: Second Sight Medical Products (EYES) & RTI Surgical (RTIX)
www.americanbankingnews.com - August 30 at 12:18 PM
Financial Comparison: Second Sight Medical Products (EYES) & ConforMIS (CFMS)Financial Comparison: Second Sight Medical Products (EYES) & ConforMIS (CFMS)
www.americanbankingnews.com - August 29 at 6:18 PM
Second Sight Stock Climbs on FDA NodSecond Sight Stock Climbs on FDA Nod
www.baystreet.ca - August 28 at 6:15 PM
Second Sight Receives Conditional FDA Approval to Begin First Orion Human Clinical StudySecond Sight Receives Conditional FDA Approval to Begin First Orion Human Clinical Study
finance.yahoo.com - August 28 at 6:15 PM
Analyzing Second Sight Medical Products (EYES) and Glaukos Corporation (GKOS)Analyzing Second Sight Medical Products (EYES) and Glaukos Corporation (GKOS)
www.americanbankingnews.com - August 19 at 2:26 AM
Head-To-Head Survey: Second Sight Medical Products (NASDAQ:EYES) vs. Trivascular Technologies (TRIV)Head-To-Head Survey: Second Sight Medical Products (NASDAQ:EYES) vs. Trivascular Technologies (TRIV)
www.americanbankingnews.com - August 10 at 8:22 PM
Second Sight Medical Products (EYES) CEO Will McGuire on Q2 2017 Results - Earnings Call Transcript - Seeking AlphaSecond Sight Medical Products' (EYES) CEO Will McGuire on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 2 at 5:13 AM
Second Sight Medical Products, Inc. (EYES) Announces Quarterly  Earnings Results, Beats Estimates By $0.03 EPSSecond Sight Medical Products, Inc. (EYES) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - August 1 at 9:29 PM
Investor Network: Second Sight Medical Products, Inc. to Host Earnings CallInvestor Network: Second Sight Medical Products, Inc. to Host Earnings Call
finance.yahoo.com - August 1 at 7:07 PM
Second Sight Reports Second Quarter 2017 Financial ResultsSecond Sight Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 1 at 7:07 PM
Second Sight Medical Products posts 2Q lossSecond Sight Medical Products posts 2Q loss
finance.yahoo.com - August 1 at 7:07 PM
Form 8-K SECOND SIGHT MEDICAL For: Jul 26 - StreetInsider.comForm 8-K SECOND SIGHT MEDICAL For: Jul 26 - StreetInsider.com
www.streetinsider.com - July 28 at 4:41 PM

Social Media

Financials

Chart

Second Sight Medical Products (NASDAQ EYES) Chart for Tuesday, November, 21, 2017
Loading chart…

This page was last updated on 11/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.